Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-19

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

NCT03497767

Metastatic Non Small Cell Lung Cancer

COMPLETED PHASE2

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NCT05033691

NSCLC EGFR Gene Mutation EGF-R Positive Non-Small Cell Lung Cancer +2 more

RECRUITING NA

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

NCT03535363

NSCLC Non-small Cell Lung Cancer

COMPLETED PHASE1

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

NCT04233021

Non Small Cell Lung Cancer Metastatic Leptomeningeal Metastasis Brain Metastases +1 more

COMPLETED PHASE2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796

Metastatic Non-small Cell Lung Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Non-small Cell Stage IV Brain Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SRS + Osimertinib

Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.

Group Type ACTIVE_COMPARATOR

Osimertinib

Intervention Type DRUG

Daily oral osimertinib

Stereotactic radiotherapy

Intervention Type RADIATION

1-5 fractions of stereotactic radiotherapy

Osimertinib alone

Osimertinib 80mg PO daily

Group Type EXPERIMENTAL

Osimertinib

Intervention Type DRUG

Daily oral osimertinib

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Osimertinib

Daily oral osimertinib

Intervention Type DRUG

Stereotactic radiotherapy

1-5 fractions of stereotactic radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide written informed consent by patient or legally acceptable representative
* Meets the criteria in the approved regulatory indication for first line treatment with osimertinib and agree to the restrictions, monitoring, and dose-adjustment criteria stipulated in the associated product label
* Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations)
* No prior systemic therapy except neoadjuvant, adjuvant or concurrent chemotherapy given greater than 3 months prior to enrollment on study
* Asymptomatic or minimally symptomatic brain metastases (ie. Headache, nausea, or seizure responsive to dexamethasone/analgesic/antiepileptic on stable doses of medications for a minimum of 3 days)
* Brain metastases must meet the following criteria on a diagnostic MRI: at least one lesion can be classified as measurable disease per RANO-BM, ≤ 10 brain or brainstem metastases, ≤ 30 mm and brainstem metastases must be ≤ 5 mm, metastases \> 5 mm from the optic nerve or chiasm
* ECOG performance status 0-2
* Life expectancy \> 6 months
* Willing to abstain from sexual activity or willing to use double-barrier method during sexual intercourse

Exclusion Criteria

* Previous treatment with osimertinib, or any other EGFR TKI
* Patient with symptomatic brain metastases causing any neurologic deficit (not including headache, nausea, or medically controlled seizure)
* Multiple sclerosis
* Pacemaker or MRI-incompatible metal in the body
* Allergy to gadolinium MRI contrast
* Brain metastasis requiring surgery for decompression
* Leptomeningeal disease
* Previous cranial RT, or surgery for brain metastases
* Uncontrolled systemic lupus erythematosis, scleroderma or other connective tissue disorders considered a contraindication for radiotherapy
* Active cancer from another anatomical site within 5 years (non-melanomatous skin and cervical cancers permitted)
* Any medical or non-medical issue that would render patient unable to reliably complete regular QOL and neurocognitive assessments
* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
* Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater
* Patients with symptomatic CNS metastases who are neurologically unstable
* Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
* Patients taking any drugs that are known to prolong QT interval that can't be withdrawn prior to Osimertinib
* Pregnant or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No